Aptose Biosciences Analyst Ratings
Aptose Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 887.01% | Cantor Fitzgerald | → $38 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 211.69% | Piper Sandler | $37 → $12 | Maintains | Overweight |
| 08/11/2023 | 497.4% | RBC Capital | $40 → $23 | Maintains | Outperform |
| 08/11/2023 | 497.4% | HC Wainwright & Co. | $12 → $23 | Maintains | Buy |
| 08/11/2023 | 289.61% | Oppenheimer | $50 → $15 | Maintains | Outperform |
| 06/12/2023 | 497.4% | HC Wainwright & Co. | $12 → $23 | Maintains | Buy |
| 06/12/2023 | 887.01% | Cantor Fitzgerald | $6 → $38 | Maintains | Overweight |
| 06/12/2023 | 1198.7% | Oppenheimer | $9 → $50 | Maintains | Outperform |
| 06/07/2023 | 861.04% | Piper Sandler | $45 → $37 | Maintains | Overweight |
| 06/07/2023 | 938.96% | RBC Capital | $75 → $40 | Maintains | Outperform |
| 05/09/2023 | 133.77% | Oppenheimer | → $9 | Reiterates | → Outperform |
| 05/09/2023 | 29.87% | RBC Capital | → $5 | Reiterates | → Outperform |
| 05/09/2023 | 211.69% | HC Wainwright & Co. | → $12 | Reiterates | → Buy |
| 03/27/2023 | 107.79% | Canaccord Genuity | $13 → $8 | Maintains | Buy |
| 03/24/2023 | 29.87% | RBC Capital | → $5 | Reiterates | → Outperform |
| 11/02/2022 | 29.87% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 05/10/2022 | 55.84% | RBC Capital | $7 → $6 | Maintains | Outperform |
| 12/21/2021 | 211.69% | HC Wainwright & Co. | $14 → $12 | Maintains | Buy |
| 11/12/2021 | 263.64% | HC Wainwright & Co. | $9 → $14 | Maintains | Buy |
| 03/24/2021 | 133.77% | Oppenheimer | $8 → $9 | Maintains | Outperform |
| 02/20/2020 | 315.58% | Maxim Group | → $16 | Initiates Coverage On | → Buy |
| 01/09/2020 | 159.74% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 08/07/2019 | 55.84% | HC Wainwright & Co. | $8.5 → $6 | Reiterates | → Buy |
| 01/25/2019 | 55.84% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 11/16/2018 | 29.87% | B. Riley Securities | → $5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/07/2023 | 887.01% | 康托·菲茨杰拉德 | →$38 | 重申 | 超重→超重 |
| 2023年08月11日 | 211.69% | 派珀·桑德勒 | $37→$12 | 维护 | 超重 |
| 2023年08月11日 | 497.4% | 加拿大皇家银行资本 | $40→$23 | 维护 | 跑赢大盘 |
| 2023年08月11日 | 497.4% | HC Wainwright公司 | $12→$23 | 维护 | 买 |
| 2023年08月11日 | 289.61% | 奥本海默 | $50→$15 | 维护 | 跑赢大盘 |
| 2023/06/12 | 497.4% | HC Wainwright公司 | $12→$23 | 维护 | 买 |
| 2023/06/12 | 887.01% | 康托·菲茨杰拉德 | $6→$38 | 维护 | 超重 |
| 2023/06/12 | 1198.7% | 奥本海默 | $9→$50 | 维护 | 跑赢大盘 |
| 06/07/2023 | 861.04% | 派珀·桑德勒 | $45→$37 | 维护 | 超重 |
| 06/07/2023 | 938.96% | 加拿大皇家银行资本 | $75→$40 | 维护 | 跑赢大盘 |
| 05/09/2023 | 133.77% | 奥本海默 | →$9 | 重申 | →跑赢大盘 |
| 05/09/2023 | 29.87% | 加拿大皇家银行资本 | →$5 | 重申 | →跑赢大盘 |
| 05/09/2023 | 211.69% | HC Wainwright公司 | →$12 | 重申 | →购买 |
| 03/27/2023 | 107.79% | 卡纳科特·格纳奇 | $13→$8 | 维护 | 买 |
| 03/24/2023 | 29.87% | 加拿大皇家银行资本 | →$5 | 重申 | →跑赢大盘 |
| 11/02/2022 | 29.87% | 加拿大皇家银行资本 | $6→$5 | 维护 | 跑赢大盘 |
| 2022年05月10日 | 55.84% | 加拿大皇家银行资本 | $7→$6 | 维护 | 跑赢大盘 |
| 2021/12/21 | 211.69% | HC Wainwright公司 | $14→$12 | 维护 | 买 |
| 2021年11月12日 | 263.64% | HC Wainwright公司 | $9→$14 | 维护 | 买 |
| 03/24/2021 | 133.77% | 奥本海默 | $8→$9 | 维护 | 跑赢大盘 |
| 02/20/2020 | 315.58% | Maxim集团 | →$16 | 开始承保 | →购买 |
| 1/09/2020 | 159.74% | 派珀·桑德勒 | →$10 | 开始承保 | →超重 |
| 2019年08月07日 | 55.84% | HC Wainwright公司 | $8.5→$6 | 重申 | →购买 |
| 2019年01月25日 | 55.84% | 奥本海默 | →$6 | 开始承保 | →跑赢大盘 |
| 2018年11月16日 | 29.87% | B.莱利证券 | →$5 | 开始承保 | →购买 |
What is the target price for Aptose Biosciences (APTO)?
Aptose Biosciences(APTO)的目标价格是多少？
The latest price target for Aptose Biosciences (NASDAQ: APTO) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $38.00 expecting APTO to rise to within 12 months (a possible 887.01% upside). 16 analyst firms have reported ratings in the last year.
康托·菲茨杰拉德于2023年9月7日报道了Aptose Biosciences(纳斯达克：APTO)的最新目标价。这家分析公司将目标价定为38美元，预计APTO将在12个月内升至(可能上涨887.01%)。过去一年，有16家分析公司公布了评级。
What is the most recent analyst rating for Aptose Biosciences (APTO)?
Aptose Biosciences(APTO)的最新分析师评级是多少？
The latest analyst rating for Aptose Biosciences (NASDAQ: APTO) was provided by Cantor Fitzgerald, and Aptose Biosciences reiterated their overweight rating.
纳斯达克(Sequoia Capital：APTO)的最新分析师评级由康托·菲茨杰拉德提供，Aptose Biosciences重申其增持评级。
When is the next analyst rating going to be posted or updated for Aptose Biosciences (APTO)?
Aptose Biosciences(APTO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptose Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptose Biosciences was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Aptose Biosciences的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Aptose Bioscience的上一次评级是在2023年9月7日提交的，所以你应该预计下一次评级将在2024年9月7日左右的某个时候提供。
Is the Analyst Rating Aptose Biosciences (APTO) correct?
分析师对Aptose Biosciences(APTO)的评级正确吗？
While ratings are subjective and will change, the latest Aptose Biosciences (APTO) rating was a reiterated with a price target of $0.00 to $38.00. The current price Aptose Biosciences (APTO) is trading at is $3.85, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Aptose Biosciences(APTO)评级被重申，目标价在0.00美元至38.00美元之间。Aptose Biosciences(APTO)目前的交易价格为3.85美元，在分析师的预测范围内。